Valuation
- Market cap
- 30,382,000
- Revenue TTM
- $0
- Net income TTM
- $-10,440,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 158,300
- Avg volume
- 728,490
- Day's range
- $0.71 – $0.76
- Shares out
- 42,022,000
- Stochastic %K
- 34%
- Beta
- 1.48
- Analysts
- Strong Sell
- Price target
- $7.25
Company profile
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is u...
Show more
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- Phone
- 786 432 9792
- Website
- https://mirapharmaceuticals.com
- Address
- 1200 Brickell Avenue, Suite 1950 #1183, Miami, United States
Latest news
No headlines yet.
